Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Octatron is an oral antioxidant nutraceutical supplement formulated as a combination of multivitamins and minerals in amino acid chelated form. Its primary components typically include vitamins A, C, and E, along with essential minerals such as selenium, zinc, and molybdenum, often supplemented with citrus bioflavonoids. The product is designed to modulate the oxidant-antioxidant balance and mitigate oxidative stress, which is a known factor in cellular damage and impaired oocyte quality. In the clinical setting, Octatron has been investigated as an adjunct therapy for female infertility, specifically for women undergoing controlled ovarian stimulation for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). A randomized controlled trial conducted at the Egyptian International Fertility IVF Center evaluated its efficacy in improving metaphase II oocyte quality and clinical pregnancy rates, though it did not demonstrate a statistically significant benefit over control groups in women with unexplained infertility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Octatron.